Renowned Biopharmaceutical Company Reports 12-month Survival Rates For Glioblastoma Patients

Biodexa's MTX110 Shows Promising Survival Rates in Recurrent Glioblastoma Patients: A Beacon of Hope.

This post may contain affiliate links. If you purchase anything through these affiliated links, I may earn a commission.

Biodexa Pharmaceuticals, a world-renowned biopharmaceutical company, recently reported encouraging 12-month survival rates from its MAGIC-G1 study of MTX110 in recurrent glioblastoma patients. This breakthrough news brings a glimmer of…